Viewing Study NCT02558959


Ignite Creation Date: 2025-12-24 @ 2:40 PM
Ignite Modification Date: 2026-01-05 @ 5:58 PM
Study NCT ID: NCT02558959
Status: COMPLETED
Last Update Posted: 2018-02-13
First Post: 2015-09-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Sponsor: Zhejiang University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module